A compound having the general formula
##STR00001##
wherein A is selected from the group consisting of
##STR00002##
to the formation of a compound of the general formula (1)
##STR00003##
and a compound of the general formula (2)
##STR00004##
respectively, and pharmaceutically acceptable salts thereof, wherein
R.sup.1 is a member selected from the group consisting of CF.sub.3,
OSO.sub.2CF.sub.3, OSO.sub.2CH.sub.3, SOR.sup.4, SO.sub.2R.sup.4,
COR.sup.4, CN, OR.sup.4, NO.sub.2, CONHR.sup.4, 3-thiophene, 2-thiophene,
3-furane, 2-furane, F, Cl, Br and I, wherein R.sup.4 is as defined below;
R.sup.2 is a member selected from the group consisting of H, F, Cl, Br,
I, CN, CF.sub.3, CH.sub.3, OCH.sub.3, OH, NH.sub.2, SO.sub.mCF.sub.3,
O(CH.sub.2).sub.mCF.sub.3, SO.sub.2N(R.sup.4).sub.2, CH.dbd.NOR.sup.4,
COCOOR.sup.4, COCOON(R.sup.4).sub.2, (C.sub.1-C.sub.8)alkyl,
(C.sub.3-C.sub.8)cykloalkyl, CH.sub.2OR.sup.4, CH.sub.2(R.sup.4).sub.2,
NR.sup.4SO.sub.2CF.sub.3, NO.sub.2, at phenyl at positions 2, 4, 5 or 6,
wherein x and R.sup.4 are as defined below; R.sup.3 is a member selected
from the group consisting of hydrogen, CF.sub.3, CH.sub.2CF.sub.3,
(C.sub.1-C.sub.8)alkyl, (C.sub.3-C.sub.8)cykloalkyl,
(C.sub.4-C.sub.9)cycloalkylmethyl, (C.sub.2-C.sub.8)alkenyl,
(C.sub.2-C.sub.8)alkynyl, 3,3,3-tri-fluoropropyl, 4,4,4-trifluorobutyl,
CH.sub.2SCH.sub.3, CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2F,
CH.sub.2CF.sub.3, phenylethyl, 2-thiopheneethyl and 3-thiopheneethyl;
R.sup.4 is a member selected from the group consisting of hydrogen,
CF.sub.3, CH.sub.2CF.sub.3, (C.sub.1-C.sub.8)alkyl,
(C.sub.3-C.sub.8)cycloalkyl, (C.sub.4-C.sub.9)cycloalkylmethyl,
(C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl,
3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, 2-tetrahydrofurane and
3-tetrahydrofurane; X is selected from the group consisting of N and
sp.sup.3-hybridized C; Y is selected from the group consisting of O and,
when R.sub.3 represents H, OH; Z is selected from the group consisting of
H and OH when X is sp.sup.3-hybridized C or Z represents O or an
electronic lone-pair when X is N; the dashed line represents a bond when
X is sp.sup.2-hybridized C or is absent when X is N; m is an integer 1 or
2; n is an integer 1-3; provided that when n in Formula 1 is 2, R.sup.1
is SO.sub.2CH.sub.3 and R.sup.2 is H R.sup.3 does not represent n-propyl.
The invention also relates to a pharmaceutical preparation containing said
compound, the use of said compound for the manufacture of a
pharmaceutical composition and a method for the treatment of a disorder
in the central nervous system of a patient using said compound.
